Expression of Interest

Key Dates

April 2011
Registration open

Early December 2011
Call for Late Breaking Abstracts

31 January 2012
Early Bird Registration Deadline

17 February 2012
Author registration deadline

25 - 29 March 2012
Symposium dates

Hosted By

The Australian Atherosclerosis Society

Organising Committee

The Local Organising Committee is composed of 6 highly regarded members of the atherosclerosis community, all of which have extensive experience in developing and delivering educational conferences. The Local Organising Committee will be further assisted by an International Program Committee who will consult on the scientific program development. Members of the International Program Committee include Peter Libby (USA), John Kastelein (The Netherlands) and Emilio Moriguchi (Brasil).

Members of the Local Organising Committee are:

Prof Kerry Anne Rye (Chair)

Kerry Anne Rye Kerry-Anne Rye is currently Associate Director and Head of the Lipid Research Group at The Heart Research Institute in Sydney, Australia. She is also a conjoint Professor in the Faculty of Medicine at the University of Sydney. Professor Rye has chaired the organising committees of several national and international meetings. She is an Associate Editor of the Journal of Lipid Research, an Editorial Board Member of Arteriosclerosis, Thrombosis and Vascular Biology and Editor of HDL Forum, a peer-reviewed website that provides up-to-date information about recent advances in basic and clinical cardiovascular research for healthcare professionals. Her main areas of expertise are in identifying relationships between HDL metabolism and structure, She has a particular interest in understanding new and previously identified functions of HDL in the context of atherosclerosis and diabetes. She has published more that 130 peer reviewed articles and reviews on these topics and has also co-authored two handbooks on HDL and CETP inhibition.

Prof Philip Barter

Phillip Barter Philip Barter is director of The Heart Research Institute, in Sydney, Australia and also a Professor of Medicine at the University of Sydney. He is currently President Elect of the International Atherosclerosis Society. He is also a member of the International Task Force for Prevention of Coronary Heart Disease and is a member of the executive of the International Chair on Cardiometabolic Risk. His basic research interests are plasma lipids and lipoproteins, specifically high density lipoproteins. His clinical research involves participation in clinical trials. He was a member of the steering committees of the FIELD study and of the TNT Study and was chairman of the steering committee of the ILLUMINATE study. He is currently a member of the steering committee of the DalOutcomes and is co-chair of the DEFINE trial; these are studies of new CETP inhibitors. He has published more than 200 peer-reviewed research papers on plasma lipids and lipoproteins and atherosclerosis. He has also written handbooks on HDL and CETP inhibitors. Recognising that atherosclerosis has become a major global epidemic, he is committed to the development of atherosclerosis education programs in countries beyond North America and Western Europe, including South and Southeast Asia, South and Central America, the Middle East and Africa.

Dr Peter Clifton

Prof Peter Clifton is an endocrinologist with an interest in obesity, type 2 diabetes, lipids and CVD. After 22 years at CSIRO he moved to baker IDI Heart and Diabetes Institute in 2009. He is the Coauthor of the CSIRO Total Well Being diet books and the health heart Book and has over 200 peer-reviewed publications.

A/Prof Jeffrey Cohn

Jeffrey Cohn is the leader of the Nutrition and Metabolism Group at the Heart Research Institute and is an Associate Professor in the Faculty of Medicine at the University of Sydney. He has been involved in both scientific and clinical research pertaining to drug and diet effects on lipid and lipoprotein metabolism. Much of his work has focused on the atherogenicity of triglyceride-rich lipoproteins (TRL), the quantification of TRL remnants, and the plasma kinetics of TRL apolipoproteins in the fed and fasted state. He has published over 95 scientific papers in peer-reviewed journals and is on the Editorial Board of “Cholesterol”, “Clinical Biochemistry” and the “Journal of Lipid Research”. He is an Associate Editor of “Atherosclerosis” and a Section Editor of “Current Opinion in Lipidology”.

Professor Karin Jandeleit-Dahm

Professor Karin Jandeleit-Dahm is a clinician scientist and Co-Head of the Diabetes Division at the Baker IDI Heart and Diabetes Institute. She is a NHMRC Senior research fellow and as a nephrologist has clinical appointments at the Alfred Hospital and at the Baker IDI clinics. Furthermore, she holds Professorships in Medicine with Monash University (Adjunct) and the University of Hannover, Germany.

A/Prof Richard O’Brien

Richard O'Brien Richard O’Brien is Clinical Dean of Medicine at the University of Melbourne, Austin and Northern Clinical Schools. He is Director of the Lipid Service and a senior endocrinologist at the Austin Hospital and holds the position of visiting scientist at the Baker Heart Research Institute.
After completing undergraduate training at the Austin Hospital in Melbourne, he undertook further studies in diabetic renal disease with Prof. George Jerums, completing a PhD entitled “Diabetic Nephropathy: Early Pathophysiology and Therapeutic Intervention”. He continued his research at the Austin Hospital until 1991 when he moved to Monash Medical Centre. Prof. O’Brien spent 15 years as Head of Diabetes at Monash Medical Centre and moved back to the Austin Hospital in 2007 to take up his current position. Over the last 10 years his research work has focused mainly on aspects of atherosclerosis in diabetes including lipid abnormalities and endothelial dysfunction and he has authored numerous scientific papers on these subjects. Richard O’Brien is a past President of the Australian Atherosclerosis Society and is chair of the Australian Diabetes Society Expert Committee on Hyperlipidaemia. In addition to his undergraduate responsibilities in his role as Clinical Dean, Richard O’Brien is strongly committed to post graduate teaching, and has a long standing interest in continuing education for general practitioners. He is a frequent speaker at educational and scientific meetings in Australia and overseas. Prof. O’Brien also continues to be involved in direct patient care on a day to day basis and maintains ongoing research interests in diabetes and atherosclerosis at the Baker Institute and at the Austin Hospital.

Clinical A/Prof David Sullivan.

David Sullivan is a physician and chemical pathologist in the Department of Clinical Biochemistry at Royal Prince Alfred Hospital and Associate Professor, Faculty of Medicine at the University of Sydney Central Clinical School. Previous clinical posts have included the MRC Lipoprotein Unit, Royal Postgraduate School of Medicine, Hammersmith Hospital, London and co-ordination of international clinical studies from the World Health Organization reference lipid laboratory in Wageningen, Netherlands. David has a long-term interest in lipid metabolism with particular emphasis on the dietary component of gene – environment interactions contributing to cardiovascular disease. He has been involved in the early use of many forms of lipid-lowering intervention and his other main interest is the improvement of detection and management of severe inherited dyslipidaemia. David has served on numerous clinical committees including the management committees of the LIPID and FIELD trials and he is a past president of national atherosclerosis and clinical nutrition societies.

Prof Gerald Watts

Gerald Watts is a graduate of Imperial College, University of London, and received his clinical and research training in the UK. He is a consultant physician, specializing in diabetes, dyslipidaemia and cardiovascular medicine, and is the present Chair of Familial Hypercholesterolaemia-Australasia. He is Head of the Metabolic Research Centre and Lipid Disorders Clinic, Royal Perth Hospital, and Winthrop Professor of Medicine in the School of Medicine and Pharmacology, University of Western Australia. His research interests include clinical lipidology and diabetes, use of tracers for investigating lipid metabolism, and development of healthcare models for FH. Professor Watts is actively involved in undergraduate medical teaching and supervisors several PhD students and post-doctoral research fellows. He has authored over 300 published works, including scientific articles, reviews, book chapters and monographs. He is on the editorial board of four journals: Atherosclerosis, Clinical Science, Practical Diabetes International and British Journal of Diabetes and Vascular Disease.

ISA 2012